ALKAL1
ALK and LTK ligand 1
Also known as: ALKL1_HUMAN, AUGB, FAM150A, UNQ9433
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q6UXT8
- Gene
- ALKAL1
- Ensembl
- ENSG00000196711
- Chromosome
- 8
- Canonical length
- 129 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
Enables protein tyrosine kinase activator activity and signaling receptor binding activity. Involved in cell surface receptor protein tyrosine kinase signaling pathway; positive regulation of MAPK cascade; and positive regulation of neuron projection development. Is active in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
129 residues, UniProt reviewed canonical sequence.
>Q6UXT8|ALKAL1
1 MRPLKPGAPL PALFLLALAL SPHGAHGRPR GRRGARVTDK EPKPLLFLPA AGAGRTPSGS
61 RSAEIFPRDS NLKDKFIKHF TGPVTFSPEC SKHFHRLYYN TRECSTPAYY KRCARLLTRL
121 AVSPLCSQTLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ALKAL1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.56
- Highest tissue expression
- 2.2 nTPM
Expression across tissuesHPA
Tissue
- gallbladder: 2.2 nTPM
- thyroid gland: 2.2 nTPM
- urinary bladder: 1.5 nTPM
- cervix: 1.1 nTPM
- colon: 1 nTPM
- salivary gland: 0.8 nTPM
Single-cell type
- salivary ionocytes: 30 nCPM
- cholangiocytes: 16 nCPM
- urothelial cells: 13 nCPM
- breast lactating cells: 13 nCPM
- paneth cells: 7.7 nCPM
- endometrial secretory cells: 6.5 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- pons: 1.2 nTPM
- medulla oblongata: 1.1 nTPM
- hypothalamus: 0.6 nTPM
- spinal cord: 0.6 nTPM
- white matter: 0.6 nTPM
- midbrain: 0.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.85
- gnomAD pLI
- 0
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cell surface receptor protein tyrosine kinase signaling pathway
- positive regulation of ERK1 and ERK2 cascade
- positive regulation of ERK5 cascade
- positive regulation of neuron projection development
Molecular functions
- cytokine activity
- receptor signaling protein tyrosine kinase activator activity
- receptor tyrosine kinase binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ALKAL1 as an antibody target. Whether an autoantibody or antibody against ALKAL1 could matter depends on whether native ALKAL1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ALKAL1 is annotated at the cell surface, where native ALKAL1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label ALKAL1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...